½ÉÀå´ë»çÁõÈıºÇÐȸ 2023 Ãß°è½ÉÆ÷Áö¾ö : 2023-09-23
±³À°ÀÏÀÚ : 2023-09-23
±³À°Àå¼Ò : Swiss Grand Seoul (Flamingo room)
±³À°ÁÖÁ¦ : ½ÉÀå´ë»çÁõÈıºÇÐȸ 2023 Ãß°è½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ½ÉÀå´ë»çÁõÈıºÇÐȸ
´ã´çÀÚ : ±è¼±¿Á
¿¬¶ôó : 010-9222-8977
À̸ÞÀÏ : apcms@kscms.org
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í "»çÀüµî·Ï: ±³¼ö ¹× °³¿øÀÇ – 4¸¸¿ø, ÀüÀÓÀÇ, Àü°øÀÇ, ±âŸ – ¹«·á
ÇöÀåµî·Ï: ±³¼ö ¹× °³¿øÀÇ - 5¸¸¿ø, ÀüÀÓÀÇ, Àü°øÀÇ, ±âŸ – ¹«·á"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 09:00~09:20 GLP-1 with weight loss and belly fat loss ¼¹ÌÇý(¼øõÇâÀÇ´ë ±¸¹Ìº´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 09:20~09:40 GLP-1 and ASCVD Reduction Indications À¯ÁöÈñ(¿¬¼¼¿øÁÖÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 09:40~10:00 Cases of Basal Insulin and GLP-1 ±èÇ强(°¡Å縯ÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 09¿ù 23ÀÏ Flamingo room 10:00~10:20 Discussion ±è¼ºÈ¯, ¹®¼±ÁØ, Á¤¹ÌÇâ, ±è°æ¹Î(°í·ÁÀÇ´ë, ¼º±Õ°üÀÇ´ë, °¡Å縯ÀÇ´ë, ¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 10:50~11:10 Mind-Body Intervention for stress reduction and Cardiometabolic Health À念¿ì(°¡ÃµÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 11:10~11:30 Appropriate exercise education for the elderly and frail population ±è¹ÌÁö(°æÈñ´ë ÀϹݴëÇпø À¶ÇÕÀÇ°úÇаú)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 11:30~11:50 Diet and Cardiometabolic health : Lp(a) revisited ½Å¹ÎÁ¤(°í·Á´ë ¹ÙÀÌ¿À½Ã½ºÅÛÀÇ°úÇкÎ)
Åä·Ð 09¿ù 23ÀÏ Flamingo room 11:50~12:10 Discussion ¹Ú°æ, ¹Ú»ó¹Î, ¼Àçºó, À̹ÎÈ£(¿µ³²´ëÇб³, À»ÁöÀÇ´ë, ¼¿ïÀÇ´ë, ¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 12:10~12:25 Cutting Edge Care of Pitavastatin with Ezetimibe Combination Therapy ¼¿ø¿ì(ÇѸ²ÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 12:25~12:40 Prevention of CVD in hypertension with diabetes ±èÇöÁø(ÇѾçÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 13:30~13:50 Understanding TG metabolism and its Relationship with Cardiovascular Risk ±è³²ÈÆ(°í·ÁÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 13:50~14:10 Evidence-based Overview for TG Lowering Therapy ±èÇзÉ(¼¿ïÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 14:10~14:30 Integrating TG lowering Strategies into ASCVD Prevention Á¶»óÈ£(ÇѸ²ÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 09¿ù 23ÀÏ Flamingo room 14:30~14:50 Discussion ¹Î¼¼Èñ, °º´±Ô, Á¤ÀçÈÆ, °ø¹Î±Ô(¿ï»êÀÇ´ë, ÀÎÁ¦ÀÇ´ë, ±¹¸³Áß¾ÓÀÇ·á¿ø, ¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 14:50~15:10 GLP1-receptor agonists are better ÀÓ¼ö(¼¿ïÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 15:10~15:30 SGLT2 inhibitors are better ÃÖ¼ºÈÆ(ÇѸ²ÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 09¿ù 23ÀÏ Flamingo room 15:30~15:50 Discussion È«¼øÁØ, ÃÖÈ¿ÀÎ, À̽ÃÈÆ, È«ÁØÈ(°í·ÁÀÇ´ë, ¼º±Õ°üÀÇ´ë, °¡ÃµÀÇ´ë, À»ÁöÀÇ´ë)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 16:10~16:30 Tackling the Dual Epidemics of Diabetes and Obesity: Insights from Clinical Trials (SURMOUNT2 and OASIS -PIONEER PLUS) ¹Ú¼¼Àº(¼º±Õ°üÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 16:30~16:50 Advancements in Cardiometabolic Disease Management: Highlights from LBTs (PRECISION and BrigHTN) ¾ÈÈ¿¼®(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)
±³À°½Ã°£ 09¿ù 23ÀÏ Flamingo room 16:50~17:10 Beyond Statins: Emerging Strategies for Managing Dyslipidemia (CLEAR-OUTCOMES and OCEAN(a)-DOSE) À§Áø(°¡ÃµÀÇ´ë ½ÉÀå³»°ú)
Åä·Ð 09¿ù 23ÀÏ Flamingo room 17:10~17:30 Discussion À¯½Â±â, ¹ÚÈÆÁØ, ¹®Á¤±Ù, ¹Ú¼ÒÈñ(ÀÌÈÀÇ´ë, °¡Å縯ÀÇ´ë, °¡ÃµÀÇ´ë, ÀÎÁ¦ÀÇ´ë)